Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3891642rdf:typepubmed:Citationlld:pubmed
pubmed-article:3891642lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0024117lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0001927lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0015840lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0004906lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:3891642lifeskim:mentionsumls-concept:C0148299lld:lifeskim
pubmed-article:3891642pubmed:issue5lld:pubmed
pubmed-article:3891642pubmed:dateCreated1985-8-21lld:pubmed
pubmed-article:3891642pubmed:abstractTextThirty patients suffering from acute exacerbations of chronic obstructive lung disease were divided on a random basis into two groups and allocated, for purposes of comparison, to treatment either with a combination of salbutamol plus beclomethasone dipropionate or with fenoterol. The two treatments being compared were evaluated on the basis of ventilatory function parameters (FEV1, FVC), bronchodilatation tests and subjective and objective clinical investigations regarding the bronchopulmonary picture and the tolerance of the drugs. All investigations and tests were performed according to identical procedures both before and after 4 weeks' treatment, and the data obtained evaluated by statistical analysis. The results proved positive for both preparations, though the combination of salbutamol plus beclomethasone dipropionate produced a greater bronchodilator effect, facilitated a more sensitive response to the bronchodilator on the part of bronchial beta2-adrenergic receptors, and was characterized by better tolerance.lld:pubmed
pubmed-article:3891642pubmed:languageenglld:pubmed
pubmed-article:3891642pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:citationSubsetIMlld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3891642pubmed:statusMEDLINElld:pubmed
pubmed-article:3891642pubmed:monthMaylld:pubmed
pubmed-article:3891642pubmed:issn0174-4879lld:pubmed
pubmed-article:3891642pubmed:authorpubmed-author:GiovanniniMMlld:pubmed
pubmed-article:3891642pubmed:authorpubmed-author:PerriGGlld:pubmed
pubmed-article:3891642pubmed:authorpubmed-author:SpadaEElld:pubmed
pubmed-article:3891642pubmed:issnTypePrintlld:pubmed
pubmed-article:3891642pubmed:volume23lld:pubmed
pubmed-article:3891642pubmed:ownerNLMlld:pubmed
pubmed-article:3891642pubmed:authorsCompleteYlld:pubmed
pubmed-article:3891642pubmed:pagination274-8lld:pubmed
pubmed-article:3891642pubmed:dateRevised2010-10-25lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:meshHeadingpubmed-meshheading:3891642-...lld:pubmed
pubmed-article:3891642pubmed:year1985lld:pubmed
pubmed-article:3891642pubmed:articleTitleSalbutamol plus beclomethasone dipropionate (Ventolin Flogo) vs. fenoterol (Dosberotec) in chronic obstructive lung disease therapeutic strategy: a 4-week clinical trial.lld:pubmed
pubmed-article:3891642pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3891642pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3891642pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3891642pubmed:publicationTypeRandomized Controlled Triallld:pubmed